[Evaluation of amikacin (BB-K8) in ophthalmological field (author's transl)].
D000038:Abscess / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000613:Aminobutyrates / Q000031:analogs & derivatives; D000818:Animals; D001082:Aqueous Humor / Q000032:analysis; D001424:Bacterial Infections / Q000188:drug therapy; D002481:Cellulitis / Q000188:drug therapy; D003228:Conjunctiva; D003607:Dacryocystitis / Q000188:drug therapy; D009877:Endophthalmitis / Q000188:drug therapy; D005128:Eye Diseases / Q000188:drug therapy*; D005141:Eyelid Diseases / Q000188:drug therapy; D005260:Female; D005839:Gentamicins / Q000494:pharmacology; D006726:Hordeolum / Q000188:drug therapy; D006801:Humans; D007267:Injections; D007273:Injections, Intramuscular; D007612:Kanamycin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D007634:Keratitis / Q000188:drug therapy; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D011817:Rabbits; D013210:Staphylococcus / Q000187:drug effects; D013530:Surgical Wound Infection / Q000188:drug therapy; D013666:Tears / Q000032:analysis
D000613:Aminobutyrates; D005839:Gentamicins; D007612:Kanamycin